Powder: -20°C for 3 years | In solvent: -80°C for 1 year
AKR1C3-IN-9 是选择性的醛酮还原酶 1C3 (AKR1C3) 抑制剂 (IC50= 8.92 nM)。AKR1C3-IN-9 显著逆转在耐药乳腺癌细胞系对 Doxorubicin (DOX) 耐药性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 283 | 现货 | ||
5 mg | ¥ 663 | 现货 | ||
10 mg | ¥ 987 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,320 | 现货 | ||
100 mg | ¥ 4,880 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | AKR1C3-IN-9 is a selective Aldo-keto Reductase 1C3 (AKR1C3) inhibitor (IC50= 8.92 nM). AKR1C3-IN-9 can significantly reverse the Doxorubicin (DOX) resistance in a resistant breast cancer cell line. |
靶点活性 | AKR1C3:8.92 nM |
体外活性 | AKR1C3-IN-9 (compound 24) (10-100 μ M; 72 h and 96 h) exhibits weak anti proliferation effect on three breast cancer cell lines (MDA-MB-231, MCF-7) with the inhibition range of 100 μ M. AKR1C3-IN-9 (10 μ M, 25 μ M, 50 μ M; 72 hours) and 10-50 μ M DOX synergistically inhibits the proliferation of MCF-7 cells. AKR1C3-IN-9 (10 μ M; 8 d) and 50 μ M DOX synergistically inhibits the proliferation and clonal survival of MCF-7/DOX cell lines, thereby restoring sensitivity to DOX [1]. |
分子量 | 352.38 |
分子式 | C20H20N2O4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 75.0 mg/mL (212.8 mM), Sonication and heating to 60℃ are recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.8378 mL | 14.1892 mL | 28.3785 mL | 70.9461 mL |
5 mM | 0.5676 mL | 2.8378 mL | 5.6757 mL | 14.1892 mL | |
10 mM | 0.2838 mL | 1.4189 mL | 2.8378 mL | 7.0946 mL | |
20 mM | 0.1419 mL | 0.7095 mL | 1.4189 mL | 3.5473 mL | |
50 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4189 mL | |
100 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7095 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
AKR1C3-IN-9 Metabolism NADPH Inhibitor inhibitor inhibit